TScan Therapeutics (TCRX) executive compensation, 2026 proxy

Gavin MacBeath, Ph.D., Chief Executive Officer and Director, was paid $2.8M in 2025, up 59% from $1.8M the year before.

Filed
April 17, 2026
Annual meeting
May 20, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.8M+59% vs prior year
CEO Target Bonus
60%Percentage of base salary
CFO Target Bonus
40%Percentage of base salary
CMO Target Bonus
40%Percentage of base salary
CEO Base Salary
$665,000For fiscal 2025

How Ph.D. was paid

$2.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary24%Option awards71%Non-equity incentive5%All other compensation0%

Named executive officers

ExecutiveTotal
Gavin MacBeath, Ph.D.Chief Executive Officer and Director$2,801,450
Jason A. AmelloChief Financial Officer and Treasurer$1,275,995
Chrystal Louis, M.D., M.P.H.Chief Medical Officer$1,609,600

What changed and why

  • $2.8MChief executive officer Gavin MacBeath received total compensation of $2,801,450 for fiscal year 2025.
  • Stock option awards represented the largest portion of executive compensation across named executive officers in 2025.
  • $14,000All named executive officers received $14,000 in matching 401(k) plan contributions as all other compensation in 2025.
  • Cash incentive bonuses were awarded based on a combination of corporate and individual performance goals.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.